POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China

This study has been completed.
Sponsor:
Collaborator:
Centers for Disease Control and Prevention, China
Information provided by (Responsible Party):
Li Li, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT01052415
First received: January 19, 2010
Last updated: February 22, 2012
Last verified: February 2012
  Purpose

In this project, UCLA's Center for Community Health (CCH) will develop an efficacious intervention trial integrating both individual and structural components to reduce HIV- related stigma among service providers in China and therefore benefit people living with HIV/AIDS (PLWHA).

The purpose of this study is to develop a feasible, practical and low cost intervention strategy that will prevent and/or reduce the negative effects of HIV-related stigma among health service providers in China.

This project will be conducted in two provinces and proceed in two phases. In Phase 1, confidential focus groups will take place with small samples of service providers and hospital administrators to finalize the intervention activities, and the investigators will also test and finalize the Audio Computer-Assisted Self-Interview (ACASI) assessment measures and implementation procedures with the same group of service providers. During Phase 1 a small sample of patients will anonymously test the paper-pencil baseline survey. Equal number of samples will be selected from two counties of each province. The findings from Phase 1 will be used to develop intervention, and revise assessment for Phase 2.


Condition Intervention
HIV-related Stigma
Patient Satisfaction
Provider-patient Interaction
Behavioral: Cognitive behavioral sessions

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Prevention
Official Title: POL and Access Intervention to Reduce HIV Stigma Among Service Providers in China

Resource links provided by NLM:


Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • HIV related stigma [ Time Frame: 6-month and 12-month follow-up ] [ Designated as safety issue: No ]
  • Patient satisfaction [ Time Frame: 6-mont and 12-month follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Universal precaution [ Time Frame: 6-month and 12-month follow-up ] [ Designated as safety issue: No ]

Enrollment: 5400
Study Start Date: September 2007
Study Completion Date: August 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Standard care
Service providers and HIV patients, offered intervention at the end of study
Experimental: Intervention
Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
Behavioral: Cognitive behavioral sessions
Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
Other Name: Intervention, service providers, HIV-related stigma

Detailed Description:

HIV is a serious problem and HIV-related stigma in the medical setting is impeding every step in the battle against HIV in China. The number of annual reported HIV infections in China has increased steadily. The proposed study will be the first randomized controlled intervention trial that specifically targets stigma and access to universal precautions in medical settings, and is implemented at multiple sites in Yunnan and Fujian. Among the two target provinces, Yunnan has the highest number of reported HIV infections in China whereas Fujian is one of the provinces reporting the lowest HIV prevalence rate in China. With the trial implemented in Yunnan and Fujian Provinces simultaneously, we will examine the program's efficacy in two provinces that vary dramatically in HIV prevalence and infection routes. We propose to include two provinces that represent China as a whole, due to the varied HIV rates and infection routes in diverse regions; thus allowing us to disentangle the relations among HIV-related stigma, fear of infection, and HIV prevalence.

Specific Aim 1: To examine whether providers in the intervention hospitals, compared to providers in the standard care condition, will demonstrate positive attitudinal outcomes, including an increase in comfort in working with PLH and a decrease in unrealistic fear of infection at work, prejudicial attitudes, and support of coercive policies.

Specific Aim 2: To examine whether providers in the intervention hospitals, compared to providers in the standard care condition, will demonstrate more positive behavioral outcomes, including an increase in adherence to universal precaution, routine treatment and referrals, confidentiality protection, diffusion of positive messages with co-workers, and a decrease in critical incidents.

Specific Aim 3: To explore whether patients in the intervention hospitals, compared to patients at hospitals in the standard care condition, will report a decreased level of perceived unfair treatment and increased service satisfaction, service utilization, and treatment adherence.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Service providers: 18 years and older, who work at the county hospital that is participating in the study, including doctors, nurses and lab technicians, and who provide informed consent.
  • Hospital administrators: 18 years and older, who work at the county hospital that is participating in the study as administrators, and who provide informed consent.
  • Patients: Age 18 and older, who receive treatment from STD, obstetrics/gynecology or HIV care department at the participating hospital, and who provide informed consent.

Exclusion Criteria:

  • Those who cannot give informed consent (e.g., intoxicated)
  • Those who have a permanent disability (e.g., deaf, serious mental illness, mental retardation).
  • Anyone who does not meet the inclusion criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01052415

Locations
United States, California
UCLA Semel Institute-Center for Community Health
Los Angeles, California, United States, 90024
Sponsors and Collaborators
University of California, Los Angeles
Centers for Disease Control and Prevention, China
Investigators
Principal Investigator: Li Li, PhD UCLA Semel Institute, Center for Community Health
  More Information

No publications provided

Responsible Party: Li Li, Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT01052415     History of Changes
Other Study ID Numbers: R01MH081778
Study First Received: January 19, 2010
Last Updated: February 22, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of California, Los Angeles:
HIV
Stigma
POL
Service providers
China
Universal precaution

ClinicalTrials.gov processed this record on October 22, 2014